Dr. Keith Crandall co-authored paper on pulmonary exacerbations (PEx) in persons with cystic fibrosis (CF) in Frontiers in Medicine and manuscript on Therapeutic beta-lactam dosages and broad-spectrum antibiotics was accepted by Scientific Reports


January 16, 2023

Dr. Keith Crandall co-authored publication in Frontiers in Medicine and co-authored manuscript in journal Scientific Reports

Dr. Keith Crandall recently co-authored a publication on "Using metabolic potential within the airway microbiome as predictors of clinical state in persons with cystic fibrosis" in Frontiers in Medicine. More information can be found here and below. 

Shumyatsky G, Burrell A, Chaney H, Sami I, Koumbourlis AC, Freishtat RJ, Crandall KA, Zemanick ET and Hahn A (2023) Using metabolic potential within the airway microbiome as predictors of clinical state in persons with cystic fibrosis. Front. Med. 9:1082125. doi: 10.3389/fmed.2022.1082125.

 

Dr. Keith Crandall co-authored manuscript on "Therapeutic beta-lactam dosages and broad-spectrum antibiotics" was recently accepted by the journal Scientific Reports. More information can be found below. 

Hahn A, Burrell A, Chaney H, Sami I, Koumbourlis AC, Freishtat RJ, Crandall KA, and Zemanick ET. Therapeutic beta-lactam dosages and broad-spectrum antibiotics are associated with reductions in microbial richness and diversity in persons with cystic fibrosis. Sci Rep 2023; Accepted 4 Jan 2023 [SREP-22-01003B].